Muniesa Cristina, Gallardo Fernando, García-Doval Ignacio, Estrach M Teresa, Combalia Andrea, Morillo-Andújar Mercedes, De la Cruz-Vicente Fátima, Machan Salma, Moya-Martínez Cristina, Rovira Roger, Sanchez-Gonzalez Blanca, Acebo Elvira, Amutio Elena, Peñate Yeray, Losada-Castillo Maria Del Carmen, García-Muret M Pilar, Iznardo Helena, Román-Curto Concepción, Cañueto Javier, Fernández-de-Misa Ricardo, Flórez Ángeles, Izu Rosa María, Torres-Navarro Ignacio, Zayas Ana, Pérez-Paredes Gema, Blanes Mar, Yanguas J Ignacio, Pérez-Ferriols Amparo, Callejas-Charavia Marta, Ortiz-Romero Pablo Luis, Pérez-Gil Amalia, Prieto-Torres Lucia, González-Barca Eva, Servitje Octavio
Department of Dermatology, Hospital Universitari de Bellvitge, Universitat de Barcelona, IDIBELL, L'Hospitalet de Llobregat, Barcelona, Spain.
Department of Dermatology, Hospital de Viladecans, Viladecans, Barcelona, Spain.
J Eur Acad Dermatol Venereol. 2023 Jan;37(1):57-64. doi: 10.1111/jdv.18563. Epub 2022 Sep 9.
Brentuximab vedotin (BV) has been approved for CD30-expressing cutaneous T-cell lymphoma (CTCL) after at least one previous systemic treatment. However, real clinical practice is still limited.
To evaluate the response and tolerance of BV in a cohort of patients with CTCL.
We analysed CTCL patients treated with BV from the Spanish Primary Cutaneous Lymphoma Registry (RELCP).
Sixty-seven patients were included. There were 26 females and the mean age at diagnosis was 59 years. Forty-eight were mycosis fungoides (MF), 7 Sézary syndrome (SS) and 12 CD30+ lymphoproliferative disorders (CD30 LPD). Mean follow-up was 18 months. Thirty patients (45%) showed at least 10% of CD30+ cells among the total lymphocytic infiltrate. The median number of BV infusions received was 7. The overall response rate (ORR) was 67% (63% in MF, 71% in SS and 84% in CD30 LPD). Ten of 14 patients with folliculotropic MF (FMF) achieved complete or partial response (ORR 71%). The median time to response was 2.8 months. During follow-up, 36 cases (54%) experienced cutaneous relapse or progression. The median progression free survival (PFS) was 10.3 months. The most frequent adverse event was peripheral neuropathy (PN) (57%), in most patients (85%), grades 1 or 2.
These results confirm the efficacy and safety of BV in patients with advanced-stage MF, and CD30 LPD. In addition, patients with FMF and SS also showed a favourable response. Our data suggest that BV retreatment is effective in a proportion of cases.
本妥昔单抗（BV）已被批准用于治疗至少接受过一次全身治疗的表达CD30的皮肤T细胞淋巴瘤（CTCL）。然而，实际临床应用仍然有限。
评估BV在一组CTCL患者中的疗效和耐受性。
我们分析了来自西班牙原发性皮肤淋巴瘤登记处（RELCP）接受BV治疗的CTCL患者。
纳入67例患者。其中女性26例，诊断时的平均年龄为59岁。48例为蕈样肉芽肿（MF），7例为塞扎里综合征（SS），12例为CD30+淋巴增殖性疾病（CD30 LPD）。平均随访时间为18个月。30例患者（45%）在淋巴细胞浸润中显示至少10%的CD30+细胞。接受BV输注的中位数为7次。总缓解率（ORR）为67%（MF中为63%，SS中为71%，CD30 LPD中为84%）。14例亲毛囊性MF（FMF）患者中有10例达到完全或部分缓解（ORR 71%）。缓解的中位时间为2.8个月。随访期间，36例（54%）出现皮肤复发或进展。无进展生存期（PFS）的中位数为10.3个月。最常见的不良事件是周围神经病变（PN）（57%），大多数患者（85%）为1或2级。
这些结果证实了BV在晚期MF和CD30 LPD患者中的疗效和安全性。此外，FMF和SS患者也显示出良好的反应。我们的数据表明，BV再治疗在一部分病例中是有效的。
